Advanced Therapies Week 2025
Welcome to Advanced Therapies Week 2025, the ultimate launchpad for the Cell and Gene Therapy (CGT) community!
For over 20 years, the event has been the premier destination for knowledge sharing, relationship building, and deal-making. We are dedicated to helping biotech and pharmaceutical companies advance on their commercialization journey and bringing the industry one step closer to delivering life-changing treatments to patients.
Date: January 20-23, 2025
Location:Kay Bailey Hutchison Convention Center – Dallas, Texas
Booth: 665
CATALENT SPONSOR WELCOME RECEPTION
Date: Monday, January 20th, 2025
Time: 7:00 PM – 11:30 PM
Location: Gilley’s, Dallas
Address:1135 Botham Jean Blvd, Dallas, TX 75215
JOIN US!
Visit us at booth 665 to meet our experts and learn how partnering with Catalent can accelerate your cell and gene therapy programs to the clinic. Our expertise covers all areas of cell and gene therapy including iPS cell lines & differentiation, autologous & allogeneic therapies, plasmid DNA, viral vectors, process development, integrated & standalone analytical services and clinical & commercial manufacturing.
Complete the form to schedule a meeting with Catalent at Advanced Therapies Week 2025.
SPEAKING PRESENTATIONS
Talk by Frederic Cedrone at iPSC symposium titled – iPSC Forum: Developing Efficient Stem Cell Therapies
Title: Leveraging Partnerships to Accelerate the Journey From iPSC Line to Patient Cure
Time: 3:30 pm
Date: January 21, 2025
Location: Theatre 7
Fireside chat between George Buchman from Catalent and Nathalie Clément from Siren Biotechnology during session titled – Disrupting Gene Therapy Manufacturing.
Time: 2:20-3:20 pm
Date: January 22, 2025
Location: Theatre 2
SPEAKERS
Frederic Cedrone
Vice President, Corporate Innovation
Catalent
George Buchman
Gene Therapy Research Fellow
Catalent
ABOUT CATALENT CELL & GENE THERAPY
Catalent Cell & Gene Therapy is an industry-leading technology, development, and manufacturing partner for advanced therapeutics. Its comprehensive cell therapy portfolio includes a wide range of expertise across a variety of cell types including CAR-T, TCR, TILs, NKs, iPSCs, and MSCs. With deep expertise in viral vector development, scale-up and manufacturing for gene therapies and viral vectors, Catalent is a full-service partner for plasmid DNA, adeno-associated viral (AAV), lentiviral and other viral vectors, and oncolytic viruses. An experienced and innovative partner, Catalent Cell & Gene Therapy has a global network of dedicated development, clinical and commercial manufacturing facilities for small- and large-scale programs.
